candesartan has been researched along with Aldosteronism with Hyperplasia of the Adrenal Cortex in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although the pharmacology of ROMK channels is still being developed, channel inhibitors have been identified and shown to cause natriuresis and diuresis, in the absence of any significant kaliuresis, on acute oral dosing to rats or dogs." | 1.43 | The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype. ( Alonso-Galicia, M; Corona, A; Felix, JP; Garcia, ML; Gill, C; Hampton, C; Kaczorowski, GJ; Kohler, M; Liu, J; Metzger, JM; Ormes, J; Owens, K; Pai, LY; Pasternak, A; Price, O; Priest, BT; Rasa, C; Roy, S; Shah, K; Sullivan, KA; Tang, H; Thomas-Fowlkes, B; Tong, V; Xiao, J; Zhou, X, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hampton, C | 1 |
| Zhou, X | 1 |
| Priest, BT | 1 |
| Pai, LY | 1 |
| Felix, JP | 1 |
| Thomas-Fowlkes, B | 1 |
| Liu, J | 1 |
| Kohler, M | 1 |
| Xiao, J | 1 |
| Corona, A | 1 |
| Price, O | 1 |
| Gill, C | 1 |
| Shah, K | 1 |
| Rasa, C | 1 |
| Tong, V | 1 |
| Owens, K | 1 |
| Ormes, J | 1 |
| Tang, H | 1 |
| Roy, S | 1 |
| Sullivan, KA | 1 |
| Metzger, JM | 1 |
| Alonso-Galicia, M | 1 |
| Kaczorowski, GJ | 1 |
| Pasternak, A | 1 |
| Garcia, ML | 1 |
1 other study available for candesartan and Aldosteronism with Hyperplasia of the Adrenal Cortex
| Article | Year |
|---|---|
The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype.
Topics: Animals; Bartter Syndrome; Benzimidazoles; Benzofurans; Biphenyl Compounds; Blood Pressure; Dogs; Do | 2016 |